Molecular Interventions towards Multiple Sclerosis Treatment.
B cell receptor
T cell receptor
delivery methods
immunotherapy
monoclonal antibodies
multiple sclerosis
tolerance
vaccine
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
15 May 2020
15 May 2020
Historique:
received:
28
04
2020
revised:
11
05
2020
accepted:
12
05
2020
entrez:
21
5
2020
pubmed:
21
5
2020
medline:
21
5
2020
Statut:
epublish
Résumé
Multiple sclerosis (MS) is an autoimmune life-threatening disease, afflicting millions of people worldwide. Although the disease is non-curable, considerable therapeutic advances have been achieved through molecular immunotherapeutic approaches, such as peptides vaccination, administration of monoclonal antibodies, and immunogenic copolymers. The main aims of these therapeutic strategies are to shift the MS-related autoimmune response towards a non-inflammatory T helper 2 (Th2) cells response, inactivate or ameliorate cytotoxic autoreactive T cells, induce secretion of anti-inflammatory cytokines, and inhibit recruitment of autoreactive lymphocytes to the central nervous system (CNS). These approaches can efficiently treat autoimmune encephalomyelitis (EAE), an essential system to study MS in animals, but they can only partially inhibit disease progress in humans. Nevertheless, modern immunotherapeutic techniques remain the most promising tools for the development of safe MS treatments, specifically targeting the cellular factors that trigger the initiation of the disease.
Identifiants
pubmed: 32429225
pii: brainsci10050299
doi: 10.3390/brainsci10050299
pmc: PMC7287961
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : European Research Council
ID : GA695190
Pays : International
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14599-606
pubmed: 15306684
Curr Med Chem. 2017;24(17):1761-1771
pubmed: 28578649
Nanomedicine (Lond). 2017 Jun;12(11):1231-1242
pubmed: 28593827
Science. 1993 Feb 26;259(5099):1321-4
pubmed: 7680493
BMC Neurol. 2019 Jun 8;19(1):116
pubmed: 31176355
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5680-5
pubmed: 15056761
Nat Rev Neurol. 2015 Mar;11(3):134-42
pubmed: 25686758
Nature. 1989 Oct 12;341(6242):541-4
pubmed: 2477708
PLoS One. 2012;7(12):e50478
pubmed: 23272061
J Exp Med. 1994 Dec 1;180(6):2227-37
pubmed: 7525850
Eur J Neurol. 2015 Oct;22 Suppl 2:3-13
pubmed: 26374508
Molecules. 2014 Nov 04;19(11):17968-84
pubmed: 25375337
Mult Scler. 2010 Mar;16(3):342-50
pubmed: 20106943
CNS Neurosci Ther. 2015 Mar;21(3):222-30
pubmed: 25403984
J Neurol Sci. 1997 Nov 6;152(1):31-8
pubmed: 9395124
Nat Commun. 2015 Sep 15;6:8244
pubmed: 26372309
J Neuroimmunol. 2006 Mar;172(1-2):121-31
pubmed: 16371235
Curr Neurol Neurosci Rep. 2013 Nov;13(11):394
pubmed: 24061646
J Neuroimmunol. 2014 May 15;270(1-2):13-21
pubmed: 24680062
Immunity. 1995 Oct;3(4):397-405
pubmed: 7584131
Immunology. 2008 Jan;123(1):66-78
pubmed: 17944900
Neurology. 1993 Apr;43(4):655-61
pubmed: 8469318
BMC Neurol. 2013 Jul 11;13:80
pubmed: 23841877
Ann Neurol. 2000 Nov;48(5):758-65
pubmed: 11079539
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Mol Pharm. 2014 Aug 4;11(8):2623-30
pubmed: 24712391
Front Immunol. 2017 Jul 26;8:896
pubmed: 28798751
J Clin Invest. 2002 Jun;109(12):1635-43
pubmed: 12070311
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Clin Immunol. 2009 May;131(2):202-15
pubmed: 19230777
Neurology. 2004 Dec 28;63(12 Suppl 6):S15-8
pubmed: 15623664
Isr J Med Sci. 1989 Dec;25(12):686-9
pubmed: 2533187
Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):217-29
pubmed: 15853744
Neurol Ther. 2018 Jun;7(1):103-128
pubmed: 29542041
JAMA Neurol. 2013 Sep 1;70(9):1105-9
pubmed: 23817921
BMC Neurol. 2019 Jan 7;19(1):5
pubmed: 30616596
FASEB J. 2011 Dec;25(12):4211-21
pubmed: 21859892
Mult Scler Relat Disord. 2019 Jan;27:52-60
pubmed: 30317071
J Neurol. 2019 May;266(5):1182-1193
pubmed: 30820738
Immunotargets Ther. 2014 Dec 16;4:1-11
pubmed: 27471707
Nat Med. 2000 Oct;6(10):1167-75
pubmed: 11017150
Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):281-6
pubmed: 16387849
Neurology. 1996 Apr;46(4):907-11
pubmed: 8780061
Expert Rev Neurother. 2013 Dec;13(12 Suppl):3-9
pubmed: 24289836
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Mult Scler Relat Disord. 2019 Jun;31:157-164
pubmed: 31005729
Neurotherapeutics. 2016 Oct;13(4):895-904
pubmed: 27324388
Pharmacol Rep. 2019 Dec 18;:
pubmed: 32048246
N Engl J Med. 2008 Feb 14;358(7):676-88
pubmed: 18272891
J Immunol. 2015 Feb 1;194(3):1039-46
pubmed: 25556244
CNS Drugs. 2018 May;32(5):401-410
pubmed: 29761344
Autoimmun Rev. 2007 Aug;6(7):469-75
pubmed: 17643935
Pharmacol Res. 2016 Aug;110:122-130
pubmed: 27181095
J Immunol. 1994 Oct 1;153(7):3326-36
pubmed: 7522258
Mediators Inflamm. 2016;2016:2847232
pubmed: 27239100
Ann Neurol. 2008 May;63(5):611-20
pubmed: 18481290
J Neurol. 2002 Feb;249(2):212-8
pubmed: 11985389
Expert Opin Biol Ther. 2016 Jun;16(6):827-839
pubmed: 26914737
Curr Opin Microbiol. 2012 Jun;15(3):300-9
pubmed: 22647353
Neurosciences (Riyadh). 2018 Apr;23(2):129-134
pubmed: 29664454
Theranostics. 2020 Feb 10;10(7):3138-3150
pubmed: 32194859
Arch Neurol. 2007 Oct;64(10):1407-15
pubmed: 17698695
N Engl J Med. 2006 Mar 2;354(9):899-910
pubmed: 16510744
Mol Cell Probes. 2020 Jun;51:101530
pubmed: 32035108
Mult Scler J Exp Transl Clin. 2019 Dec 2;5(4):2055217319887191
pubmed: 31832225
Mult Scler. 2000 Aug;6(4):255-66
pubmed: 10962546
J Immunol. 1994 Mar 1;152(5):2510-9
pubmed: 7510746
Neurology. 2018 Mar 13;90(11):e955-e962
pubmed: 29467307
Lancet Neurol. 2010 Jul;9(7):727-39
pubmed: 20610348
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9595-600
pubmed: 15983366
Ann Neurol. 2010 Nov;68(5):593-601
pubmed: 21031576
Neurology. 2014 Feb 18;82(7):573-81
pubmed: 24453078
Neurol Sci. 2000 Dec;21(6):383-403
pubmed: 11441577
Mult Scler. 2018 Dec;24(14):1862-1870
pubmed: 30415593
Lancet. 2012 Nov 24;380(9856):1829-39
pubmed: 23122650
Acta Neurol Belg. 1994;94(2):112-5
pubmed: 7518632
Nat Med. 1996 Oct;2(10):1109-15
pubmed: 8837609
Neurology. 2018 Nov 13;91(20):e1893-e1901
pubmed: 30305449
Neurology. 1995 Jul;45(7):1268-76
pubmed: 7617181
J Immunol. 1998 May 15;160(10):5037-44
pubmed: 9590253
Neurology. 2018 May 15;90(20):e1805-e1814
pubmed: 29695594
Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8463-8470
pubmed: 30962374
Neurol Neuroimmunol Neuroinflamm. 2017 Dec 15;5(1):e417
pubmed: 29259995
Mult Scler. 2018 Apr;24(4):535-539
pubmed: 28304217
Ther Adv Neurol Disord. 2015 Jan;8(1):31-45
pubmed: 25584072
Ther Adv Neurol Disord. 2009 Mar;2(2):115-28
pubmed: 21180646
Clin Immunol. 2012 Jan;142(1):76-83
pubmed: 21163708
J Immunol Res. 2016;2016:5392623
pubmed: 27703987
Mult Scler Relat Disord. 2019 May;30:236-243
pubmed: 30844611
J Neuroimmunol. 2007 May;186(1-2):164-76
pubmed: 17451814
Neurol Ther. 2018 Jun;7(1):59-85
pubmed: 29243029
J Control Release. 2020 May 10;321:372-415
pubmed: 32061621
Lancet Neurol. 2018 May;17(5):405-415
pubmed: 29545067
Ther Adv Neurol Disord. 2011 May;4(3):139-68
pubmed: 21694816
Sci Rep. 2017 Feb 13;7:42372
pubmed: 28205558
Neurology. 2009 Sep 1;73(9):696-701
pubmed: 19720976
Nat Med. 2000 Oct;6(10):1176-82
pubmed: 11017151
Expert Rev Neurother. 2008 Mar;8(3):351-60
pubmed: 18345967
Neurology. 2010 Jun 8;74(23):1860-7
pubmed: 20530322
Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11270-5
pubmed: 22745170
Sci Transl Med. 2013 Jun 5;5(188):188ra75
pubmed: 23740901
Acta Neurol Scand. 2018 Jan;137(1):117-124
pubmed: 28901547
Biomedicines. 2019 Mar 14;7(1):
pubmed: 30875812
Neurology. 1993 Apr;43(4):662-7
pubmed: 8469319
J Immunol. 2011 Feb 15;186(4):1887-90
pubmed: 21289312
Lancet Neurol. 2010 May;9(5):520-32
pubmed: 20398859
Int Arch Allergy Appl Immunol. 1953;4(4):285-8
pubmed: 13096152
PLoS One. 2013 May 30;8(5):e64888
pubmed: 23738007
Int Immunol. 1993 Sep;5(9):1159-65
pubmed: 7694644
Clin Immunol. 2004 Nov;113(2):155-60
pubmed: 15451472
Acta Biomater. 2010 Aug;6(8):3072-80
pubmed: 20144748
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
Lancet. 1954 May 22;266(6821):1055-7
pubmed: 13164324
Front Immunol. 2015 Nov 09;6:569
pubmed: 26617604
Nat Rev Immunol. 2012 Sep;12(9):669-77
pubmed: 22918468
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679
Clin Immunol. 2012 Jan;142(1):49-56
pubmed: 21367665
Immunotargets Ther. 2013 Jul 22;2:61-71
pubmed: 27471689
Nat Rev Rheumatol. 2017 Sep;13(9):525-537
pubmed: 28701761
Science. 1991 Jan 25;251(4992):430-2
pubmed: 1989076
J Neurol Sci. 2003 Feb 15;206(2):165-71
pubmed: 12559505
Acta Neurol Scand. 2003 Jan;107(1):7-11
pubmed: 12542507
CNS Neurol Disord Drug Targets. 2018;17(2):113-118
pubmed: 29589548
J Clin Neurosci. 2019 Jan;59:229-231
pubmed: 30348586
Expert Rev Neurother. 2013 Dec;13(12 Suppl):11-9
pubmed: 24289837
Eur J Pharm Biopharm. 2020 Apr;149:192-217
pubmed: 31982574
Exp Ther Med. 2017 Jun;13(6):3163-3166
pubmed: 28588671
Lancet. 1995 Sep 23;346(8978):807-8
pubmed: 7545769
Ann Neurol. 2009 Oct;66(4):460-71
pubmed: 19847908
Nat Rev Neurol. 2014 Apr;10(4):225-38
pubmed: 24638138
Trends Biotechnol. 2018 Jul;36(7):686-699
pubmed: 29588069
Mult Scler Relat Disord. 2019 May;30:136-140
pubmed: 30771580
Neurology. 2016 Nov 15;87(20):2074-2081
pubmed: 27760868
Science. 1994 Feb 25;263(5150):1139-43
pubmed: 7509084
Nat Neurosci. 2005 Jun;8(6):745-51
pubmed: 15895088
PLoS One. 2011;6(6):e20991
pubmed: 21677771